Eribulin trials for Breast cancer

All Eribulin trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Eribulin for Breast cancer

• A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
  NCT06435429 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 166 locations
• A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
  NCT05570253 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
  NCT06279364 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
  NCT05824975 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
  NCT07007559 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 54 locations
• LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
  NCT06387628 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Organoid-based Functional Precision Therapy for Advanced Breast Cancer
  NCT06102824 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
  NCT06268652 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
  NCT07173751 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 161 locations
• Scalp Cooling in MBC
  NCT04986579 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
  NCT06942234 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
  NCT06081959 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
  NCT07461454 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 1 location

Common questions

How many trials study Eribulin for Breast cancer?

13 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.